Sutro Biopharma, Inc. (STRO)
15.34
-0.14
(-0.90%)
USD |
NASDAQ |
Sep 18, 16:00
15.32
-0.02
(-0.13%)
After-Hours: 20:00
Sutro Biopharma Cash from Operations (Quarterly) : -38.29M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -38.29M |
| March 31, 2026 | -42.26M |
| December 31, 2025 | -26.44M |
| September 30, 2025 | -38.19M |
| June 30, 2025 | -44.72M |
| March 31, 2025 | -67.88M |
| December 31, 2024 | -71.74M |
| September 30, 2024 | -64.52M |
| June 30, 2024 | 9.455M |
| March 31, 2024 | -64.74M |
| December 31, 2023 | 14.07M |
| September 30, 2023 | -33.50M |
| June 30, 2023 | -31.20M |
| March 31, 2023 | -60.99M |
| December 31, 2022 | -23.86M |
| September 30, 2022 | 65.85M |
| June 30, 2022 | -3.186M |
| March 31, 2022 | -35.26M |
| Date | Value |
|---|---|
| December 31, 2021 | -21.58M |
| September 30, 2021 | -24.41M |
| June 30, 2021 | -5.263M |
| March 31, 2021 | -30.43M |
| December 31, 2020 | -18.88M |
| September 30, 2020 | -17.69M |
| June 30, 2020 | -12.50M |
| March 31, 2020 | -18.73M |
| December 31, 2019 | -13.16M |
| September 30, 2019 | -16.12M |
| June 30, 2019 | -15.60M |
| March 31, 2019 | -20.14M |
| December 31, 2018 | -5.935M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | -4.84M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Upstream Bio, Inc. | -35.62M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 19.36M |
| Cash from Financing (Quarterly) | -0.418M |
| Free Cash Flow | -145.62M |
| Free Cash Flow Per Share (Quarterly) | -2.311 |
| Free Cash Flow to Equity (Quarterly) | -45.40M |
| Free Cash Flow to Firm (Quarterly) | -28.43M |
| Free Cash Flow Yield | -81.26% |